Tivic Health discontinues ClearUP sinus device sales to focus on Entolimod biopharma program

Reuters03-24

<a href="https://laohu8.com/S/TIVC">Tivic Health</a> discontinues ClearUP sinus device sales to focus on Entolimod biopharma program

Tivic said it is pivoting to focus on the Entolimod product and its TLR5 platform, and it is discontinuing commercial sales of the ClearUP sinus device.
The company is positioning Entolimod for oncology supportive-care use cases, including neutropenia affecting up to 50% of cancer patients.
Tivic is seeking government procurement opportunities by pursuing BARDA funding to advance Entolimod as a medical countermeasure for acute radiation syndrome.
Velocity Bioworks, its wholly owned CDMO, reported a 200-fold manufacturing scale-up of Entolimod using 50-liter fermentation, which the company said supports domestic supply-chain control for U.S. government procurement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603240930ACCESSWRNAPR_____1151175) on March 24, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621060241?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621060241","market":"fut","top_or_hot":-1,"title":"Tivic Health discontinues ClearUP sinus device sales to focus on Entolimod biopharma program","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TIVC\">Tivic Health</a> discontinues ClearUP sinus device sales to focus on Entolimod biopharma program\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Tivic said it is pivoting to focus on the Entolimod product and its TLR5 platform, and it is discontinuing commercial sales of the ClearUP sinus device.\n        </li>\n<li>\n          The company is positioning Entolimod for oncology supportive-care use cases, including neutropenia affecting up to 50% of cancer patients.\n        </li>\n<li>\n          Tivic is seeking government procurement opportunities by pursuing BARDA funding to advance Entolimod as a medical countermeasure for acute radiation syndrome.\n        </li>\n<li>\n          Velocity Bioworks, its wholly owned CDMO, reported a 200-fold manufacturing scale-up of Entolimod using 50-liter fermentation, which the company said supports domestic supply-chain control for U.S. government procurement.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603240930ACCESSWRNAPR_____1151175) on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tivic Health discontinues ClearUP sinus device sales to focus on Entolimod biopharma program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTivic Health discontinues ClearUP sinus device sales to focus on Entolimod biopharma program\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-24 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TIVC\">Tivic Health</a> discontinues ClearUP sinus device sales to focus on Entolimod biopharma program\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Tivic said it is pivoting to focus on the Entolimod product and its TLR5 platform, and it is discontinuing commercial sales of the ClearUP sinus device.\n        </li>\n<li>\n          The company is positioning Entolimod for oncology supportive-care use cases, including neutropenia affecting up to 50% of cancer patients.\n        </li>\n<li>\n          Tivic is seeking government procurement opportunities by pursuing BARDA funding to advance Entolimod as a medical countermeasure for acute radiation syndrome.\n        </li>\n<li>\n          Velocity Bioworks, its wholly owned CDMO, reported a 200-fold manufacturing scale-up of Entolimod using 50-liter fermentation, which the company said supports domestic supply-chain control for U.S. government procurement.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603240930ACCESSWRNAPR_____1151175) on March 24, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL7Txrv:1","article_id":"2621060241","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621060241","pubTimestamp":1774359092,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tivic said it is pivoting to focus on the Entolimod product and its TLR5 platform, and it is discontinuing commercial sales of the ClearUP sinus device.The company is positioning Entolimod for oncology supportive-care use cases, including neutropenia affecting up to 50% of cancer patients.Tivic is seeking government procurement opportunities by pursuing BARDA funding to advance Entolimod as a medical countermeasure for acute radiation syndrome.Velocity Bioworks, its wholly owned CDMO, reported a 200-fold manufacturing scale-up of Entolimod using 50-liter fermentation, which the company said supports domestic supply-chain control for U.S. government procurement.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","TIVC":"Tivic Health Systems, Inc."},"translate_title":"Tivic Health停止ClearUP鼻窦设备销售，专注于Entolimod生物制药项目","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TIVC":0.9},"content_text":"Tivic Health discontinues ClearUP sinus device sales to focus on Entolimod biopharma program\n    \n\n\n          Tivic said it is pivoting to focus on the Entolimod product and its TLR5 platform, and it is discontinuing commercial sales of the ClearUP sinus device.\n        \n\n          The company is positioning Entolimod for oncology supportive-care use cases, including neutropenia affecting up to 50% of cancer patients.\n        \n\n          Tivic is seeking government procurement opportunities by pursuing BARDA funding to advance Entolimod as a medical countermeasure for acute radiation syndrome.\n        \n\n          Velocity Bioworks, its wholly owned CDMO, reported a 200-fold manufacturing scale-up of Entolimod using 50-liter fermentation, which the company said supports domestic supply-chain control for U.S. government procurement.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202603240930ACCESSWRNAPR_____1151175) on March 24, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive,productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621060241","isCrawlerRequest":true}